Last updated July 22, 2026
Key finding
Treatment with semaglutide resulted in a reduction of CAP score at 4 and at 12 months (P < .05).
This study investigated the effects of semaglutide on vascular and liver function in patients with type 2 diabetes and nonalcoholic fatty liver disease, finding significant improvements in various health markers.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study investigated the effects of semaglutide on vascular and liver function in patients with type 2 diabetes and nonalcoholic fatty liver disease, finding significant improvements in various health markers.
These findings are clinically significant as they suggest that semaglutide may not only help manage blood sugar levels in type 2 diabetes but also improve liver function and reduce cardiovascular risks. This could lead to better overall health outcomes for patients suffering from both conditions.
The study's sample size may limit the generalizability of the findings. The long-term effects of semaglutide beyond 12 months were not assessed. The study did not include a diverse population, which may affect applicability.
Published in
Publication details and source links for this paper.
Emmanouil K, Aikaterini K, George P, et al. Effects of Semaglutide on Vascular and Liver Function in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. Journal of the Endocrine Society. 2024;8(8):bvae122. doi:10.1210/jendso/bvae122
Semaglutide reduced the Controlled Attenuation Parameter (CAP) score significantly at 4 and 12 months (P < .05).
Patients showed a greater decrease in central systolic blood pressure with semaglutide compared to controls (−6% vs −4%, P = .048).
Significant reductions in pulse wave velocity (PWV) were observed in the semaglutide group (−6% vs −3.5%, P = .019).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Dipeptidyl peptidase-4 inhibitors, Semaglutide and Change in aortic pulse wave velocity from baseline to week 24, Controlled attenuation parameter, FIB-4 index, and 5 more.
This study contributes evidence to
Primary intervention
Dipeptidyl peptidase-4 inhibitors
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
16
Evidence pairs
77
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence relationship
Save evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
Dipeptidyl peptidase-4 inhibitors → Change in aortic pulse wave velocity from baseline to week 24
Dipeptidyl peptidase-4 inhibitors → Change in aortic pulse wave velocity from baseline to week 24
Dipeptidyl peptidase-4 inhibitors → Controlled attenuation parameter
Dipeptidyl peptidase-4 inhibitors → Controlled attenuation parameter
Dipeptidyl peptidase-4 inhibitors → FIB-4 index
Dipeptidyl peptidase-4 inhibitors → FIB-4 index
Dipeptidyl peptidase-4 inhibitors → Fibrosis improvement percentage
Dipeptidyl peptidase-4 inhibitors → Fibrosis improvement percentage
Dipeptidyl peptidase-4 inhibitors → NAFLD Fibrosis Score
Dipeptidyl peptidase-4 inhibitors → NAFLD Fibrosis Score
Dipeptidyl peptidase-4 inhibitors → Reduction in Augmentation Index (AIx)
Dipeptidyl peptidase-4 inhibitors → Reduction in Augmentation Index (AIx)
Dipeptidyl peptidase-4 inhibitors → Reduction in Perfused Boundary Region (PBR) at 12 months
Dipeptidyl peptidase-4 inhibitors → Reduction in Perfused Boundary Region (PBR) at 12 months
Dipeptidyl peptidase-4 inhibitors → Systolic blood pressure
Dipeptidyl peptidase-4 inhibitors → Systolic blood pressure
Semaglutide → Change in aortic pulse wave velocity from baseline to week 24
Semaglutide → Change in aortic pulse wave velocity from baseline to week 24
Semaglutide → Controlled attenuation parameter
Semaglutide → Controlled attenuation parameter
Semaglutide → Fibrosis improvement percentage
Semaglutide → Fibrosis improvement percentage
Semaglutide → Reduction in Augmentation Index (AIx)
Semaglutide → Reduction in Augmentation Index (AIx)
Semaglutide → Reduction in Perfused Boundary Region (PBR) at 12 months
Semaglutide → Reduction in Perfused Boundary Region (PBR) at 12 months
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Blood Pressure, GLP-1 Receptor Agonists and NAFLD Fibrosis Score.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Blood Pressure
Measures Blood Pressure as a key outcome.
All studies on GLP-1 Receptor Agonists
Contributes to GLP-1 Receptor Agonists evidence base.
All studies measuring NAFLD Fibrosis Score
Measures NAFLD Fibrosis Score as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
3 results
2 results
3 results
3 results
2 results
Generated from the study's connected evidence using Evidence Intelligence™.
GLP-1 Receptor Agonists may improve Blood Pressure.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Systolic blood pressure
EvidenceScore™ Strong | EvidenceScore™ 78.5 | weak positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 9 supporting studies with consistent results and a positive effect signal.
Limitations
Current evidence does not show a clear benefit of DPP-4 Inhibitors for Blood Pressure.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Systolic blood pressure
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Semaglutide may improve NAFLD Fibrosis Score.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Ranked evidence signals
NAFLD Fibrosis Score
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
Semaglutide appears to improve Change in aortic pulse wave velocity from baseline to week 24.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Change in aortic pulse wave velocity from baseline to week 24
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
